TL1 Trainee Alum, Matthew Wipperman, Publishes with Nature Communications

Posted Date:
February 22, 2021

News and Congratulations


Congratulations to Matthew Wipperman, MSC, PhD, on his publication with Nature Communication on "Gastrointestinal Microbiota Composition Predicts Peripheral Inflammatory State during Treatment of Human Tuberculosis" released on Friday, February 19th, 2021. The study research works to discover whether the makeup of gastrointestinal microbiota will have an influence on the conditions of infectious diseases and the treatment pathways/outcomes.

Dr. Wipperman's research with the TL1 award covered "Microbiomic Correlates of Tuberculosis Infection and Antimycobacterial Treatment." During his time as a TL1 trainee Dr. Wipperman was able to grow his research on microbiota and the association it contributes to the treatment of Tuberculosis. This research helped his gather infromation for his current publication with Nature Communications.

Matthew Wipperman is currently working at Regeneron as a Qualitative Translational Staff Scientist, His work on the TL1 was aided by mentors Dr. Michael Glickman, Attending Physician at Memorial Sloan Kettering; Dr. Vanni Bucci, Professor at University of Massachusetts Dartmouth; and Dr. Daniel Fitzgerald, Professor at Weill Cornell Medicine.

The CTSC TL1 Training Core Award Program supports early career development among pre- and early post-doctoral trainees by providing salary support, protected time, advanced degree training and practical skills necessary to conduct interdisciplinary Clinical and Translational Investigation in a team research environment.

Check out more information on his study written by the Weill Cornell Newsroom here.

Clinical & Translational Science Center 1300 York Ave., Box 149 New York, NY 10065